A Study of the Effect of RO4607381 on Atherosclerotic Plaque in Patients With Coronary Heart Disease
Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
This study will assess the effect of RO4607381, compared to placebo, on atherosclerotic
plaque in patients with coronary heart disease (CHD) including patients with other CHD risk
factors. After a pre-randomisation period during which positron emission tomography computed
tomography (PET/CT) and MRI will be conducted, patients will be randomized to receive either
RO4607381 600mg po daily, or placebo po daily. PET/CT and MRI scans will be taken at
intervals during the study. The anticipated time on study treatment is 2 years, and the
target sample size is 100 individuals.